Enliven Therapeutics to Present Updated ELVN-001 Phase 1a Data at ESH-iCMLf 26th John Goldman CML Conference

BOULDER, Colo., Sept. 18, 2024 – Enliven Therapeutics, Inc. (Nasdaq: ELVN), a clinical-stage company specializing in precision oncology, announced updates for the ELVN-001 Phase 1a data. This data has been chosen for an oral presentation at the European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference, scheduled for September 27-29 in Prague, Czech Republic.

ELVN-001 is a potent and selective small molecule kinase inhibitor, designed to target the BCR-ABL gene fusion, which is the oncogenic driver in patients with chronic myeloid leukemia (CML). The presentation will provide preliminary data on the safety and efficacy of this drug. Specifics of the oral presentation are as follows:

Title: Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1 in CML
Presenter: Dr. Fabian Lang, Goethe University Hospital
Session: Scientific Session 5: New drugs and combinations
Date/Time: Saturday, September 28, 2024, 3:00 - 4:20 p.m. CEST
Presentation Time: 3:35 - 3:50 p.m. CEST / 9:35 - 9:50 a.m. ET

About Enliven Therapeutics:
Enliven Therapeutics is a biopharmaceutical company in the clinical stage, committed to the development and discovery of small molecule inhibitors aimed at treating cancer. Their goal is to not only extend the lifespan of patients but also to improve their quality of life. The company's approach to precision oncology focuses on addressing both existing and emerging unmet medical needs. Their discovery process integrates deep insights into clinically validated biological targets with differentiated chemistry, resulting in therapies that have the potential to be first-in-class or best-in-class.

Enliven Therapeutics is located in Boulder, Colorado.
 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!